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Importance of implementation economics for program planning
—evaluation of CDC’s colorectal cancer control program
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Understanding the cost of initiating and operationalizing colorectal cancer (CRC) control 
programs is essential for planning successful implementation of evidence-based 
recommendations to reduce disparities in the use and quality of CRC cancer screening 
services. Currently, only about 58% of adults ages 50–75 years in the United States are up-
to-date with CRC screening recommendations; adults without health insurance have a much 
lower uptake of about 24% (Sabatino, White, Thompson, & Klabunde, 2015). Targeted 
interventions and programs, especially those focused on the uninsured and underinsured 
populations, are required to meet the population-wide target of 80% by 2018 set by The 
National Colorectal Cancer Roundtable (NCCRT, n.d.). The Community Guide contains 
several evidence-based recommendations for screening promotion interventions but there are 
very few studies on the economics of screening program implementation (Baron et al., 2010; 
Sabatino et al., 2012). There is an urgent need to increase the number of ‘implementation 
economics’ studies to develop the evidence-base to guide funding decision making, design 
cost-effective programs and ensure optimal use of limited resources. We define 
‘implementation economics’ as a sub-discipline within implementation science that focusses 
on economic evaluation related to cost (cost-of-illness analysis, program cost analysis), cost-
effectiveness, cost-benefit, cost-utility, budget impact, and cost minimization.
For more than a decade, CDC has funded and provided technical support to a range of 
grantee programs to implement CRC screening and implementation economics has been a 
cornerstone of the evaluations of these programs. Between 2005 and 2009, CDC 
administered the Colorectal Cancer Screening Demonstration Program (CRCSDP) in five 
programs [Baltimore, Maryland; St. Louis, Missouri; the entire state of Nebraska; Suffolk 
County, New York; and King, Clallam and Jefferson counties in Washington] (Centers for 
Disease Control and Prevention, 2013a). These programs provided CRC screening for low-
income, underinsured, or uninsured men and women between the ages of 50 and 64 years. In 
2009, successes and lessons learned (Centers for Disease Control and Prevention, 2013b; 
Joseph, DeGroff, Hayes, Wong, & Plescia, 2011) from the CRCSDP informed planning and 
funding of the first round of CDC’s Colorectal Cancer Control Program (CRCCP) (2009–
2015). Through the CRCCP, CDC provided funding to 22 states and 4 tribal organizations to 
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implement CRC programs starting in 2009 and another 3 states were added to the program 
in 2010. Fig. 1 provides a map of the United States highlighting the CRCCP grantees.
The CRCCP represents a new approach for disseminating evidence-based interventions and 
promoting their use while simultaneously ensuring free screening for a portion of the 
medically underserved population. The CRCCP grantees used about two thirds of their funds 
to implement the population-based promotion activities (screening promotion) and the 
remaining third to deliver direct clinical screening services for low income uninsured 
individuals (screening provision). The grantees were encouraged to tailor the program to 
their individual settings within the broad framework provided by the CDC. To implement 
screening provision the grantees partnered with numerous organizations including Federally 
Qualified Health Centers, other health care systems, State Medicaid offices, professional 
organizations, employers and worksites, and private insurers. For screening provision, all 
grantees used United States Preventive Task Force-recommended tests with some using 
colonoscopies, others using fecal-based tests and several program providing multiple 
screening tests.
Several peer-reviewed manuscripts based on the economic evaluation of the earlier CRCSDP 
have been published (Subramanian, Bobashev, & Morris, 2010; Subramanian et al., 2013; 
Tangka et al., 2008; Tangka et al., 2013). These studies contributed to the implementation 
economics literature by quantifying the cost of starting and implementing CRC screening 
programs, assessing the resources required for specific programmatic activities and 
evaluating the clinical cost of delivering screening services. In this volume of Evaluation and 
Program Planning (Hoover et al., 2017; Subramanian et al., 2017; Tangka et al., 2017) we 
present a collection of three new studies on implementation economics that provide 
additional evidence to guide future CRC screening programs. These manuscripts provide a 
comprehensive evaluation as they represent the program, clinical and patient perspectives. 
Each of these different perspectives offers a unique opportunity to understand the viewpoint 
of key stakeholders involved in operationalizing screening programs and in combination 
offer a unique opportunity to assess multi-level factors required to ensure the success of 
these programs. For instance, understanding patient motivation, facilitators and barriers is 
critical to ensure individuals initiate screening and remain compliant with recommended 
screening schedules.
In the first manuscript, Tangka et al. (2017) focus on the program perspective and provide a 
detailed review of the screening promotion interventions implemented by the CRCCP 
grantees along with the funding appropriated to each type of intervention. A key goal of the 
CRCCP was to encourage programs to adopt evidence-based interventions to promote 
screening with the aim of increasing colorectal screening at the population level. The results 
showed that all grantees engaged in at least one of The Community Guide-recommended 
strategies, including patient reminders and provider assessment, and the majority of the 
funds were expended on the strategies supported by the available evidence base. 
Approximately one-third of funding was spent on mass media which is not currently 
recommended due to lack of evidence; this finding was instrumental in shaping CDC’s 
policies that changed from broad-based recommendations to targeted specific guidance and 
education on evidence-based interventions (Centers for Disease Control and Prevention, 
Tangka and Subramanian Page 2
Eval Program Plann. Author manuscript; available in PMC 2018 March 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2015). This study did not directly assess increases in population screening use, but suggested 
that a 5% increase in CRC screening could have been achieved for less than $35 per person.
In the second manuscript, Subramanian et al. (2017) address the clinical perspective by 
comparing the non-clinical (programmatic) and clinical cost of screening programs that use 
Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) versus colonoscopy. 
Non-clinical costs include all costs not directly related to provision of clinical services such 
as cost for patient navigation, program management, quality assurance and professional 
development, partnership development and maintenance, data collection and tracking, and 
program monitoring and evaluation. Over the 3-year study period, colonoscopy programs 
had higher clinical costs per person screened than FOBT/FIT. Overall, FOBT/FIT-based and 
colonoscopy programs had similar non-clinical costs per person served of approximately 
$1000. The authors conclude that CRC screening programs incur substantial non-clinical 
costs, regardless of whether the program is colonoscopy or FOBT/FIT-based and therefore 
both non-clinical and clinical costs could be considered in future program planning and 
funding decision making.
The last manuscript in this series focuses on the patient perspective and reports on findings 
from a patient survey. Hoover et al. (2017) reveal that even when colonoscopies were 
provided free, patients incurred significant costs related to lost productivity and travel. 
Among the low income population of mostly uninsured individuals in Philadelphia, patients 
incurred an average cost of about $340 and caregivers who accompanied the patients to 
visits incurred approximately $80. These patient and caregiver costs may be important 
barriers that contribute to low CRC screening use, especially among the low-income 
population.
The lessons learned from these three papers offer valuable insight to the broad range of 
stakeholders actively engaged in CRC control initiatives. First, through the use of systematic 
data collection processes, detailed cost and resource use information can be successfully 
collected from CRC programs, providers, and clients. The data collection tools and surveys 
developed through the CRCCP evaluation provide standardized instruments for future 
research. Second, to successfully implement CRC screening promotion and provision 
activities, programs have to engage in multiple activities related to programmatic oversight 
and clinical services. Therefore, adequate funding needs to be provided so these interlinked 
activities can be established and operationalized. Third, it is important to assess costs from 
multiple perspectives, especially those incurred by patients which are often not included in 
economic evaluation of cancer screening. Costs borne by patients related to lost wages and 
transportation can be important barriers that need to be further evaluated.
Additionally lessons learned from these CRC program economic evaluations were 
incorporated in planning the second round of CRCCP funding (New CRCCP) (2015–2020) 
through which CDC funded 24 state health departments, 6 universities, and one American 
Indian tribe (Centers for Disease Control and Prevention, 2015). CDC is continuing its 
commitment to advance the science of implementation economics by supporting a 
systematic evaluation of selected current CRCCP grantees. Evaluation of the cost-
effectiveness of effective interventions can identify the most efficient use of available 
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resources, contribute to the economics evidence-base for The Community Guide, and help 
increase CRC screening rates to meet national goals (NCCRT, n.d.). These future economic 
studies will continue to build on the evidence base initiated through the publications of the 
compilation of the three papers presented in this volume of Evaluation and Program 
Planning.
Finally, the lessons learned through these studies can be generalized beyond the CRCCP and 
CRC screening to other non-communicable disease management programs. Patient 
compliance and cost-effective delivery of multi-component programs remains a challenge 
across a wide range of screening and treatment modalities including cervical and breast 
cancer screening, and hypertension and diabetes management. Performing economic 
evaluation incorporating a wide variety of perspectives can provide a more comprehensive 
understanding of facilitators and barriers to help design programs that are both efficient and 
effective in achieving their goals.
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Fig. 1. 
CDC’s Colorectal Cancer Control Program Grantees (1999–2015).
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